Press Releases

BioIVT Acquires Cypex, a Leading Manufacturer of Drug-metabolizing Enzymes

Cypex’s recombinant xenobiotic metabolizing enzymes complement BioIVT’s extensive portfolio of hepatocytes and related hepatic products for drug research and development.

Service Portfolio Expanded for Drug Delivery Research

Stable and Quality Supply of Phosphoramidites Is a Reality at BOC Sciences

As an expert in chemistry, BOC Sciences understands how important the quality of phosphoramidite is to successful oligo synthesis and remarkably, it has taken concrete actions to manufacture certified products.

Thiophenes as Heterocyclic Organic Compounds for Academic Research and Industrial Manufacturing

Peptides for Diabetes Research—a Special Offer of BOC Sciences

BOC Sciences has been constantly enriching its peptide product library for years. Its peptides for diabetes research are recently brought into focus due to the growing concerns on this problem.

BOC Sciences Shares Its Strategic Emphasis on NTPs during the Pandemic

"Whether your studies involve DNA sequencing, cDNA synthesis, RT-PCR, RCA, MDA, DNA labeling, in vitro transcription, siRNA synthesis, or RNA amplification, we stock hundreds of modified or natural NTPs to suit your various molecular biological applications," a BOC Sciences manager announces to the public.

Donepezil for Alzheimer's Disease Research

Dr. Vince Clinical Research Hires Two Industry Veterans, Bringing Over 50 Years’ Combined Research Experience

Dr. Vince Clinical Research (DVCR) today announced the addition of two key leadership roles to its Phase I research team.

H1 and Lokavant Partner on Data and Analytics to Power Next Generation Clinical Trials

H1, the connecting force for global HCP, clinical, scientific, and research information, and Lokavant, the leading clinical trial intelligence company, today announced an extensive data-and-analytics collaboration to bring enhanced automated intelligence to drug development. As part of the bi-directional partnership, Lokavant will provide performance data on global trial sites and principal investigators from thousands of studies to supplement H1’s existing Trial Landscape clinical trial repository.

BrainCheck Launches Investigator Initiated Research (IIR) Grant Program For Brain and Cognitive Disorders Research The BrainCheck IIR Grant is looking to fund research that aids in the early detection and treatment of patient pools experiencing cognit

BrainCheck announced an Investigator Initiated Research (IIR) Grant Program to help fund research for evaluation, diagnosis, treatment and care for brain related disease. This includes, but is not limited to, Alzheimer's disease and related dementias (ADRD), post-operative delirium, stroke, traumatic brain injury, and post-acute Covid “brain fog”. Awardees will be provided one-year research funding and free access to the BrainCheck platform.

Creative Peptides Delivers Phage Display Services with Versatile Peptide Library

Creative Peptides delivers phage display services with a versatile phage peptide library, hoping to assist researchers in jumpstarting peptide drug screening.

Krka Extends Use of Calyx Regulatory Information Management System based on Decade of Successful Experience

Upgrade to Calyx RIM on Microsoft Azure drives efficiencies and patient safety

New from Jackson ImmunoResearch Anti-Human IgE Antibodies

Jackson ImmunoResearch has announced a new addition to its range of products for scientists developing immunoassays for serology and diagnostics markets.

New High-Performance Air-Dryable PCR Reagents Make Simple, Cost-Effective Dried Assay Development a Reality

PCR Biosystems has launched the Air-Dryable Probe 1-Step Mix, a versatile all-in-one, air-dryable 4X RT-qPCR reagent mix for ultra-sensitive detection of RNA and DNA sequences.

Creative Biogene Launches Zebrafish Disease Models to Support Drug Discovery and Toxicology Research

IntegrateRNA Launches GalNAc-Oligonucleotide Conjugation Service to Support Oligonucleotides Therapeutic Research

Calidi Biotherapeutics Announces FDA Authorization of IND for a Phase 1 Clinical Trial of NeuroNova in Patients with Recurrent High-Grade Glioma

Calidi Biotherapeutics, a clinical-stage biotechnology company is pleased to announce that City of Hope has received FDA authorization to proceed with a phase 1 physician-sponsored clinical trial that will deliver Calidi’s cutting-edge oncolytic virotherapy platform, NSC-CRAd-S-pk7 (NeuroNova), to patients with recurrent high-grade glioma.

MicroRNA Agomir Synthesis: Supporting New Drug Research with Cutting-Edge Chemical Synthesis Technology

Creative Bioarray Offers Clonality Analysis Service to Accelerate Biopharmaceutical or Biosimilar Development

Creative Bioarray Develops Full-service Support for Transgene Mapping